Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
|Articles|August 1, 2022
Daily OTC Pearl: Men’s Bladder Control
Author(s)Saro Arakelians, PharmD
Men’s Bladder Control supplements promote bladder and prostate health.
Advertisement
OTC/Lifestyle Pearl of the Day: Men’s Bladder Control
Indication: Men’s Bladder Control supplements promote bladder and prostate health.
Insight:
- Take 1 capsule per day, 60 minutes before bedtime, or as recommended by a health care provider.
- Do not consume alcohol, drive, or operate machinery after taking this product.
- Keep out of reach of children.
- Do not exceed recommended dose.
- Do not purchase if outer seal is broken or damaged.
- When using nutritional supplements, please consult a physician if undergoing treatment for a medical condition or if pregnant or lactating.
Source:
Advertisement
Related to this article
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5